Tahnoun bin Zayed al Nahyan—the UAE’s chess-obsessed, jiujitsu-loving intelligence chief—controls vast sums of sovereign ...

The next AI battleground isn’t only new models, it’s hardware. OpenAI’s move into AR glasses & robots signals a future of new ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...

Life's challenges often feel like navigating a maze-full of dead ends ... The publishing division specializes in self-help, fitness, motivation, inspiration, business, uplifting content, positive ...

Jan 31 (Reuters) - Maze Therapeutics (MAZE.O), opens new tab became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a ...

SoftBank is preparing to lead fresh investment into OpenAI at a $300 billion valuation, Business Insider understands — a move that would value the ChatGPT maker the same as TikTok owner ByteDance.

OpenAI used the subreddit, r/ChangeMyView, to create a test for measuring the persuasive abilities of its AI reasoning models. The company revealed this in a system card — a document outlining ...

This week, OpenAI and the White House accused DeepSeek of something akin to theft. In a flurry of press statements, they said the Chinese upstart had bombarded OpenAI's chatbots with queries and ...

which are the advanced algorithms behind chatbots such as OpenAI’s ChatGPT. Maze Therapeutics, a South San Francisco-based human genetics biotech, set IPO terms to 7.8 million shares at $15-$17 ...

Feb 2 (Reuters) - Generative artificial intelligence heavyweight OpenAI launched a new AI tool on Sunday called "deep research", which it said conducts multi-step research on the internet for ...